Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Mar 12

PMID 33708205

Citations 34

Authors

Zhiling Yan

Huanxin Zhang

Jiang Cao

Cheng Zhang

Hui Liu

Hongming Huang

Hai Cheng

Jianlin Qiao

Ying Wang

Yan Wang

Lei Gao

Ming Shi

Wei Sang

Feng Zhu

Depeng Li

Haiying Sun

Qingyun Wu

Yuekun Qi

Hujun Li

Xiangmin Wang

Zhenyu Li

Hong Liu

Junnian Zheng

Wenbin Qian

Xi Zhang

Kailin Xu

Affiliations

Soon will be listed here.

Abstract

Clinical trials have confirmed that chimeric antigen receptor (CAR) T cell therapies are revolutionizing approaches for treating several relapsed or refractory hematological tumors. Cytokine release syndrome (CRS) is an adverse event with high incidence during CAR-T treatment. A further understanding of the characteristics and related risk factors of CRS is important for effective management. A total of 142 patients with relapsed or refractory acute lymphocyte leukemia (ALL), lymphoma, or multiple myeloma (MM) received lymphodepletion chemotherapy followed by infusion of CAR-T cells. The characteristics of CRS at different time points after treatment were monitored and risk factors were analyzed. The incidence of CRS for ALL, lymphoma, and multiple myeloma were 82%, 90%, and 90% respectively. Fever was observed on a median of day 3 for ALL, day 1 for lymphoma, and day 8.5 for MM after CAR-T cell infusion, and the duration was different between grade 1-2 CRS and grade 3-5 CRS. Disease types, peak concentration of IL-6, and CRP were associated with CRS. For patients with ALL, numbers of lymphoblast in bone marrow before lymphodepletion, peak concentration of IL-6, and CRP were independent risk factors of CRS. Clinical stage of lymphoma patients and high tumor burden in marrow of MM patients were independent risk factors of CRS. In conclusion, the characteristics and risk factors of CRS in different B-cell hematological tumors are different and should be managed individually during CAR-T cell therapy.

Citing Articles

Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.

Li R, Grosskopf A, Joslyn L, Stefanich E, Shivva V AAPS J. 2025; 27(2):55.

PMID: 40032717 DOI: 10.1208/s12248-025-01017-w.

Emergencies in Hematology: Why, When and How I Treat?.

Duminuco A, Del Fabro V, De Luca P, Leotta D, Limoli M, Longo E J Clin Med. 2025; 13(24.

PMID: 39768494 PMC: 11728391. DOI: 10.3390/jcm13247572.

Baseline echocardiographic variables as predictors of hemodynamically significant cytokine release syndrome in adults treated with CD19 CAR T-cell therapy for hematological malignancies.

Daryanani A, Abbasi M, Gomez Ardila M, Tellez-Garcia E, Garzon-Dangond J, Lin Y Cardiooncology. 2024; 10(1):91.

PMID: 39709512 PMC: 11662545. DOI: 10.1186/s40959-024-00290-6.

Evolving strategies for addressing CAR T-cell toxicities.

Rankin A, Duncan B, Allen C, Silbert S, Shah N Cancer Metastasis Rev. 2024; 44(1):17.

PMID: 39674824 PMC: 11646216. DOI: 10.1007/s10555-024-10227-1.

CAR-armored-cell therapy in solid tumor treatment.

Liu Y, Xiao L, Yang M, Chen X, Liu H, Wang Q J Transl Med. 2024; 22(1):1076.

PMID: 39609705 PMC: 11603843. DOI: 10.1186/s12967-024-05903-3.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K . Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25. PMC: 4684949. DOI: 10.1126/scitranslmed.3008226. View

Jia H, Wang Z, Wang Y, Liu Y, Dai H, Tong C . Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation. J Hematol Oncol. 2019; 12(1):57. PMC: 6558895. DOI: 10.1186/s13045-019-0741-6. View

Lee D, Kochenderfer J, Stetler-Stevenson M, Cui Y, Delbrook C, Feldman S . T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2014; 385(9967):517-528. PMC: 7065359. DOI: 10.1016/S0140-6736(14)61403-3. View

Naidoo J, Zhang J, Lipson E, Forde P, Suresh K, Moseley K . A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events. J Natl Compr Canc Netw. 2019; 17(6):712-720. DOI: 10.6004/jnccn.2018.7268. View

Hay K, Hanafi L, Li D, Gust J, Liles W, Wurfel M . Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017; 130(21):2295-2306. PMC: 5701525. DOI: 10.1182/blood-2017-06-793141. View

Thompson J, Schneider B, Brahmer J, Andrews S, Armand P, Bhatia S . Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw. 2019; 17(3):255-289. DOI: 10.6004/jnccn.2019.0013. View

Teachey D, Lacey S, Shaw P, Melenhorst J, Maude S, Frey N . Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016; 6(6):664-79. PMC: 5448406. DOI: 10.1158/2159-8290.CD-16-0040. View

10.

Cao J, Wang G, Cheng H, Wei C, Qi K, Sang W . Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed/refractory acute lymphoblastic leukemia. Am J Hematol. 2018; 93(7):851-858. DOI: 10.1002/ajh.25108. View

11.

Sterner R, Sakemura R, Cox M, Yang N, Khadka R, Forsman C . GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2018; 133(7):697-709. PMC: 6376281. DOI: 10.1182/blood-2018-10-881722. View

12.

Neelapu S, Locke F, Bartlett N, Lekakis L, Miklos D, Jacobson C . Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017; 377(26):2531-2544. PMC: 5882485. DOI: 10.1056/NEJMoa1707447. View

13.

Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M . Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018; 24(6):739-748. DOI: 10.1038/s41591-018-0036-4. View

14.

Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler H, Schlosser H, Schlaak M . Cytokine release syndrome. J Immunother Cancer. 2018; 6(1):56. PMC: 6003181. DOI: 10.1186/s40425-018-0343-9. View

15.

Hay K, Turtle C . Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies. Drugs. 2017; 77(3):237-245. PMC: 5603178. DOI: 10.1007/s40265-017-0690-8. View

16.

Bonifant C, Jackson H, Brentjens R, Curran K . Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016; 3:16011. PMC: 5008265. DOI: 10.1038/mto.2016.11. View

17.

Yan Z, Cao J, Cheng H, Qiao J, Zhang H, Wang Y . A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 2019; 6(10):e521-e529. DOI: 10.1016/S2352-3026(19)30115-2. View

18.

Lee D, Santomasso B, Locke F, Ghobadi A, Turtle C, Brudno J . ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2018; 25(4):625-638. DOI: 10.1016/j.bbmt.2018.12.758. View

19.

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D . Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726-1737. PMC: 8202968. DOI: 10.1056/NEJMoa1817226. View